文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在首例人体干细胞试验中吸取的经验教训和仍有待吸取的经验教训。

Lessons learnt, and still to learn, in first in human stem cell trials.

机构信息

Department of Clinical Neuroscience and Wellcome-MRC Cambridge Stem Institute, John van Geest Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge CB2 0QQ, UK.

ElevateBio, Cambridge, MA 02142, USA.

出版信息

Stem Cell Reports. 2023 Aug 8;18(8):1599-1609. doi: 10.1016/j.stemcr.2022.11.019. Epub 2022 Dec 22.


DOI:10.1016/j.stemcr.2022.11.019
PMID:36563687
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10444539/
Abstract

Developing cellular therapies is not straightforward. This Perspective summarizes the experience of a group of academic stem cell investigators working in different clinical areas and aims to share insight into what we wished we knew before starting. These include (1) choosing the stem cell line and assessing the genome of both the starting and final product, (2) familiarity with GMP manufacturing, reagent validation, and supply chain management, (3) product delivery issues and the additional regulatory challenges, (4) the relationship between clinical trial design and preclinical studies, and (5) the market approval requirements, pathways, and partnerships needed.

摘要

开发细胞疗法并非易事。本观点总结了一组在不同临床领域工作的学术干细胞研究人员的经验,旨在分享我们在开始之前希望了解的见解。这些包括 (1) 选择干细胞系并评估起始和最终产品的基因组,(2) 熟悉 GMP 制造、试剂验证和供应链管理,(3) 产品输送问题和额外的监管挑战,(4) 临床试验设计与临床前研究之间的关系,以及 (5) 市场批准要求、途径和所需的合作伙伴关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61e8/10444539/fb27805e0121/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61e8/10444539/fb27805e0121/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61e8/10444539/fb27805e0121/gr1.jpg

相似文献

[1]
Lessons learnt, and still to learn, in first in human stem cell trials.

Stem Cell Reports. 2023-8-8

[2]
Administrative and research policies required to bring cellular therapies from the research laboratory to the patient's bedside.

Transfusion. 2005-10

[3]
Regional disparities in access to gene therapies in the European Union, the United States, Japan, and China.

Per Med. 2025-8

[4]
Derivation of trophoblast stem cells from naïve human pluripotent stem cells.

Elife. 2020-2-12

[5]
The Lived Experience of Autistic Adults in Employment: A Systematic Search and Synthesis.

Autism Adulthood. 2024-12-2

[6]
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.

Cochrane Database Syst Rev. 2015-10-5

[7]
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.

Cochrane Database Syst Rev. 2021-9-13

[8]
Adapting Safety Plans for Autistic Adults with Involvement from the Autism Community.

Autism Adulthood. 2025-5-28

[9]
Understanding patient pathways to Mother and Baby Units: a longitudinal retrospective service evaluation in the UK.

Health Soc Care Deliv Res. 2025-7-16

[10]
Autistic People's Experience of Empathy and the Autistic Empathy Deficit Narrative.

Autism Adulthood. 2024-9-16

引用本文的文献

[1]
Pericellular oxygen dynamics in human cardiac fibroblasts and iPSC-cardiomyocytes in high-throughput plates: insights from experiments and modeling.

J Mol Cell Cardiol Plus. 2025-6-11

[2]
Who should be included in first-in-human trials? A systematic review of reasons.

J Transl Med. 2025-6-11

[3]
Advantages and challenges of using allogeneic vs. autologous sources for neuronal cell replacement in Parkinson's disease: Insights from non-human primate studies.

Brain Res Bull. 2025-5

[4]
Risk-based pricing models and the role they might play in patients' access to new stem cell therapies.

Regen Med. 2024-12

[5]
Current Landscape of iPSC Haplobanks.

Stem Cell Rev Rep. 2024-11

[6]
Clinical translation of pluripotent stem cell-based therapies: successes and challenges.

Development. 2024-4-1

[7]
AMD and Stem Cell-Based Therapies.

Int Ophthalmol Clin. 2024-1-1

[8]
Advancing cell therapy for neurodegenerative diseases.

Cell Stem Cell. 2023-5-4

本文引用的文献

[1]
Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells.

Nat Genet. 2022-9

[2]
Strategies of pluripotent stem cell-based therapy for retinal degeneration: update and challenges.

Trends Mol Med. 2022-5

[3]
Discovery through clinical sequencing in oncology.

Nat Cancer. 2020-8

[4]
p53 inactivation unmasks histone methylation-independent WDR5 functions that drive self-renewal and differentiation of pluripotent stem cells.

Stem Cell Reports. 2021-11-9

[5]
Mutational signatures: emerging concepts, caveats and clinical applications.

Nat Rev Cancer. 2021-10

[6]
Evaluation of tools for identifying large copy number variations from ultra-low-coverage whole-genome sequencing data.

BMC Genomics. 2021-5-17

[7]
Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson's Disease to the Clinic: The Investigator's Perspective.

J Parkinsons Dis. 2021

[8]
Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution.

Cell Rep. 2021-1-26

[9]
Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports.

Front Bioeng Biotechnol. 2020-12-23

[10]
Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies.

Front Cell Dev Biol. 2020-12-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索